Latest & greatest articles for lamotrigine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lamotrigine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lamotrigine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lamotrigine

1. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. (PubMed)

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. This is an updated version of the Cochrane Review previously published in 2017.Absence seizures (AS) are brief epileptic seizures which present in childhood and adolescence. Depending on clinical features and electroencephalogram (EEG) findings they are divided into typical, atypical absences, and absences with special features. Typical absences are characterised by sudden loss of awareness (...) and an EEG typically shows generalised spike wave discharges at three cycles per second. Ethosuximide, valproate and lamotrigine are currently used to treat absence seizures. This review aims to determine the best choice of antiepileptic drug for children and adolescents with AS.To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures (AS), when compared with placebo or each other.For the latest update we searched

2019 Cochrane

2. Lamotrigine is not effective for the treatment of borderline personality disorder

Lamotrigine is not effective for the treatment of borderline personality disorder Lamotrigine is not effective for the treatment of borderline personality disorder Discover Portal Discover Portal Lamotrigine is not effective for the treatment of borderline personality disorder Published on 17 July 2018 doi: Lamotrigine, a mood-stabilising drug, is not clinically effective for the treatment of borderline personality disorder. Over one year follow up, this NIHR-funded trial did not find (...) a difference between lamotrigine and placebo for borderline personality disorder-related symptoms and behavioural problems, depressive symptoms, self-harm, social functioning or quality of life outcomes. Borderline personality disorder is a severe mental health disorder characterised by rapid and distressing fluctuations in mood, impaired social functioning and increased suicidal behaviour. Since emotional instability is a key clinical feature, it was thought treatments that help to stabilise mood might

2019 NIHR Dissemination Centre

3. Lamotrigine

Lamotrigine Top results for lamotrigine - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lamotrigine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

4. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. (PubMed)

Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. This is an updated version of the original Cochrane Review published in Issue 11, 2006 of the Cochrane Database of Systematic Reviews.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment up to 70% of individuals with active epilepsy have the potential to become (...) seizure-free, and to go into long-term remission shortly after starting drug therapy with a single antiepileptic drug (AED) in monotherapy.The correct choice of first-line AED for individuals with newly diagnosed seizures is of great importance. It is important that the choice of AEDs for an individual is made using the highest quality evidence regarding the potential benefits and harms of the various treatments.Carbamazepine or lamotrigine are recommended as first-line treatments for new onset focal

2018 Cochrane

5. Lamotrigine for people with borderline personality disorder: a RCT

Lamotrigine for people with borderline personality disorder: a RCT Lamotrigine for people with borderline personality disorder: a RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title (...) }} {{metadata.Headline}} Lamotrigine did not improve the symptoms of borderline personality disorder at 12 months. {{author}} {{($index , , , , , , , , , , , , , , , , , & . Mike J Crawford 1, * , Rahil Sanatinia 1 , Barbara Barrett 2 , Gillian Cunningham 3 , Oliver Dale 4 , Poushali Ganguli 2 , Geoff Lawrence-Smith 5 , Verity C Leeson 1 , Fenella Lemonsky 1 , Georgia Lykomitrou-Matthews 6 , Alan Montgomery 7 , Richard Morriss 7 , Jasna Munjiza 8 , Carol Paton 5 , Iwona Skorodzien 6 , Vineet Singh 9 , Wei Tan 7

2018 NIHR HTA programme

6. Lamotrigine-induced sexual dysfunction and non-adherence: case analysis with literature review (PubMed)

Lamotrigine-induced sexual dysfunction and non-adherence: case analysis with literature review Optimal anti-epileptic drug (AED) treatment maximises therapeutic response and minimises adverse effects (AEs). Key to therapeutic AED treatment is adherence. Non-adherence is often related to severity of AEs. Frequently, patients do not spontaneously report, and clinicians do not specifically query, critical AEs that lead to non-adherence, including sexual dysfunction. Sexual dysfunction prevalence (...) in patients with epilepsy ranges from 40 to 70%, often related to AEDs, epilepsy or mood states. This case reports lamotrigine-induced sexual dysfunction leading to periodic non-adherence.To report lamotrigine-induced sexual dysfunction leading to periodic lamotrigine non-adherence in the context of multiple comorbidities and concurrent antidepressant and antihypertensive pharmacotherapy.Case analysis with PubMed literature review.A 56-year-old male patient with major depression, panic disorder without

Full Text available with Trip Pro

2017 BJPsych open

7. Effectiveness of amitriptyline and lamotrigine in neuropathic pain after traumatic spinal cord injuries (PubMed)

Effectiveness of amitriptyline and lamotrigine in neuropathic pain after traumatic spinal cord injuries 28546871 2018 11 13 2058-6124 3 2017 Spinal cord series and cases Spinal Cord Ser Cases Effectiveness of amitriptyline and lamotrigine in neuropathic pain after traumatic spinal cord injuries. 16036 10.1038/scsandc.2016.36 Almeida Rodrigo L RL Department of Spinal Cord Injury/SARAH Rehabilitation Hospital Network/SARAH Brasilia, Brasilia, Distrito Federal, Brazil. Beraldo Paulo S PS

Full Text available with Trip Pro

2017 Spinal cord series and cases

8. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. (PubMed)

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. This is an updated version of the original Cochrane review originally published in 2003, Issue 3, and updated in 2005, Issue 4.Absence seizures are brief epileptic seizures which present in childhood and adolescence. Depending on clinical features and electroencephalogram (EEG) findings they are divided into typical, atypical absences, and absences with special features. Typical absences (...) are characterised by sudden loss of awareness and an EEG typically shows generalised spike wave discharges at three cycles per second. Ethosuximide, valproate and lamotrigine are currently used to treat absence seizures. This review aims to determine the best choice of antiepileptic drug for children and adolescents with typical absence seizures.To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures, when compared

Full Text available with Trip Pro

2017 Cochrane

9. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. (PubMed)

Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. This is an updated version of the original Cochrane review published in Issue 1, 2006 of the Cochrane Database of Systematic Reviews.Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment up to 70% of individuals with active epilepsy have the potential to become seizure (...) appropriate to given seizure types are compared to one another.Carbamazepine or lamotrigine are first-line recommended treatments for new onset partial seizures and as a first- or second-line treatment for generalised tonic-clonic seizures. Performing a synthesis of the evidence from existing trials will increase the precision of the results for outcomes relating to efficacy and tolerability and may assist in informing a choice between the two drugs.To review the time to withdrawal, remission and first

2016 Cochrane

10. Lamotrigine add-on for drug-resistant partial epilepsy. (PubMed)

Lamotrigine add-on for drug-resistant partial epilepsy. This is an updated version of the Cochrane review published in The Cochrane Library 2010, Issue 1.Epilepsy is a common neurological disorder, affecting almost 0.5% to 1% of the population. For nearly 30% of these people, their epilepsy is refractory to currently available drugs. Pharmacological treatment remains the first choice to control epilepsy. Lamotrigine is one of the newer antiepileptic drugs and is the topic of this review (...) . Lamotrigine in combination with other antiepileptic drugs (add-on) can reduce seizures, but with some adverse effects. The aim of this systematic review was to overview the current evidence for the efficacy and tolerability of lamotrigine when used as an adjunctive treatment for people with refractory partial epilepsy.To determine the effects of lamotrigine on (1) seizures, (2) adverse effect profile, and (3) cognition and quality of life, compared to placebo controls, when used as an add-on treatment

Full Text available with Trip Pro

2016 Cochrane

11. Lamotrigine

Lamotrigine USE OF LAMOTRIGINE IN PREGNANCY 0344 892 0909 USE OF LAMOTRIGINE IN PREGNANCY (Date of issue: December 2014 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Lamotrigine is an anticonvulsant used either as sole treatment (...) or as adjunctive treatment of focal and generalized seizures, including tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome. Lamotrigine is also used in the treatment of bipolar disorder. There is no evidence from studies of over 7,500 exposed pregnancies that use of lamotrigine in the first trimester increases the overall risk of birth defects in the offspring. Although a possible association between first trimester lamotrigine use and orofacial clefting in the infant has been

2014 UK Teratology Information Service

12. Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures. (PubMed)

Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures. Primary generalized tonic-clonic seizures are one of a number of generalized seizure types which also includes absence, myoclonic and atonic seizures. Effective control of tonic-clonic seizures is required to reduce the risk of injury and death and to improve quality of life. While most people achieve seizure control with one antiepileptic drug, around 30% do not and usually take a combination of antiepileptic (...) drugs.To assess the effectiveness of adjunctive lamotrigine for refractory primary generalized tonic-clonic seizures.We searched the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) and MEDLINE (Ovid) 1950 to June 2010. No language restrictions were imposed. We also contacted GlaxoSmithKline, manufacturers of lamotrigine.Randomised parallel or cross-over add-on trials of add-on lamotrigine for refractory primary generalized tonic-clonic

2010 Cochrane

13. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom

Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom Verdian L, Yi Y Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of the addition of rufinamide compared with topiramate or lamotrigine for children with Lennox-Gastaut Syndrome that was uncontrolled by up to three traditional

Full Text available with Trip Pro

2010 NHS Economic Evaluation Database.

14. New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate

New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate New users of the anticonvulsants gabapentin, lamotrigine, oxcarbazepine or tiagabine are at increased risk of suicidal acts compared with new users of topiramate | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser (...) at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here New users of the anticonvulsants gabapentin, lamotrigine

2010 Evidence-Based Mental Health

15. Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD)

Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD) Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

16. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. (PubMed)

Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. Childhood absence epilepsy, the most common pediatric epilepsy syndrome, is usually treated with ethosuximide, valproic acid, or lamotrigine. The most efficacious and tolerable initial empirical treatment has not been defined.In a double-blind, randomized, controlled clinical trial, we compared the efficacy, tolerability, and neuropsychological effects of ethosuximide, valproic acid, and lamotrigine in children (...) with ethosuximide (156), lamotrigine (149), or valproic acid (148) were similar with respect to their demographic characteristics. After 16 weeks of therapy, the freedom-from-failure rates for ethosuximide and valproic acid were similar (53% and 58%, respectively; odds ratio with valproic acid vs. ethosuximide, 1.26; 95% confidence interval [CI], 0.80 to 1.98; P=0.35) and were higher than the rate for lamotrigine (29%; odds ratio with ethosuximide vs. lamotrigine, 2.66; 95% CI, 1.65 to 4.28; odds ratio

Full Text available with Trip Pro

2010 NEJM Controlled trial quality: predicted high

17. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials (PubMed)

Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials There is uncertainty about the efficacy of lamotrigine in bipolar depressive episodes.To synthesise the evidence for the efficacy of lamotrigine in bipolar depressive episodes.Systematic review and meta-analysis of individual patient data from randomised controlled trials comparing lamotrigine with placebo.Individual data from 1072 participants (...) from five randomised controlled trials were obtained. More individuals treated with lamotrigine than placebo responded to treatment on both the Hamilton Rating Scale for Depression (HRSD) (relative risk (RR)=1.27, 95% CI 1.09-1.47, P=0.002) and Montgomery-Asberg Depression Rating Scale (MADRS) (RR=1.22, 95% CI 1.06-1.41, P=0.005). There was an interaction (P=0.04) by baseline severity of depression: lamotrigine was superior to placebo in people with HRSD score >24 (RR=1.47, 95% CI 1.16-1.87, P

Full Text available with Trip Pro

2009 EvidenceUpdates

18. Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia

Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia Article Text Therapeutics Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia Statistics from

2009 Evidence-Based Mental Health

19. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials

Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials Geddes JR, Calabrese JR, Goodwin GM CRD summary (...) This meta-analysis assessed the efficacy of lamotrigine in patients with acute bipolar depression. The authors concluded that it could be effective for treatment and for the prevention of relapse. This conclusion reflected the evidence presented, but the potential for error and bias throughout the review means that the reliability of this conclusion is unclear. Authors' objectives To assess the efficacy of lamotrigine in patients with acute bipolar depression. Searching In addition to the initial

Full Text available with Trip Pro

2009 DARE.

20. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis

The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.